Financhill
Sell
27

DYN Quote, Financials, Valuation and Earnings

Last price:
$9.07
Seasonality move :
-2.8%
Day range:
$8.55 - $8.90
52-week range:
$6.36 - $47.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.47x
Volume:
2.6M
Avg. volume:
3.2M
1-year change:
-79.41%
Market cap:
$982.1M
Revenue:
--
EPS (TTM):
-$3.59

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DYN
Dyne Therapeutics
-- -$0.94 -- -34.65% $39.68
BEAM
Beam Therapeutics
$13.3M -$1.09 12.91% -2.87% $44.07
NTLA
Intellia Therapeutics
$12.3M -$1.01 77.46% -32.4% $37.30
RARE
Ultragenyx Pharmaceutical
$161.7M -$1.33 9.48% -13.24% $87.84
RNA
Avidity Biosciences
$1.6M -$0.96 -21.34% -46.12% $66.56
SRPT
Sarepta Therapeutics
$529.8M $1.17 54.01% 1720.11% $47.96
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DYN
Dyne Therapeutics
$8.64 $39.68 $982.1M -- $0.00 0% --
BEAM
Beam Therapeutics
$21.16 $44.07 $2.1B -- $0.00 0% 27.92x
NTLA
Intellia Therapeutics
$11.54 $37.30 $1.2B -- $0.00 0% 25.53x
RARE
Ultragenyx Pharmaceutical
$29.51 $87.84 $2.8B -- $0.00 0% 4.67x
RNA
Avidity Biosciences
$31.45 $66.56 $3.8B -- $0.00 0% 429.95x
SRPT
Sarepta Therapeutics
$18.17 $47.96 $1.8B 20.50x $0.00 0% 0.90x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DYN
Dyne Therapeutics
-- 1.100 -- --
BEAM
Beam Therapeutics
-- 1.744 -- 8.62x
NTLA
Intellia Therapeutics
-- 2.464 -- 4.57x
RARE
Ultragenyx Pharmaceutical
-- 0.829 -- 2.03x
RNA
Avidity Biosciences
-- 0.903 -- 16.69x
SRPT
Sarepta Therapeutics
49.9% -0.560 18.15% 2.06x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DYN
Dyne Therapeutics
-- -$122.4M -- -- -- -$106.9M
BEAM
Beam Therapeutics
-- -$119.3M -43.86% -43.86% -1596.87% -$106.9M
NTLA
Intellia Therapeutics
-- -$120.8M -56.9% -56.9% -726.57% -$149.7M
RARE
Ultragenyx Pharmaceutical
$110.6M -$142.9M -205.06% -205.06% -97.23% -$182.8M
RNA
Avidity Biosciences
-- -$131.5M -29.26% -29.26% -8360.9% -$128.6M
SRPT
Sarepta Therapeutics
$607.3M -$300.4M -10.44% -20.94% -50.88% -$629.3M

Dyne Therapeutics vs. Competitors

  • Which has Higher Returns DYN or BEAM?

    Beam Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of -1462.79%. Dyne Therapeutics's return on equity of -- beat Beam Therapeutics's return on equity of -43.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$1.05 --
    BEAM
    Beam Therapeutics
    -- -$1.24 $1.1B
  • What do Analysts Say About DYN or BEAM?

    Dyne Therapeutics has a consensus price target of $39.68, signalling upside risk potential of 359.22%. On the other hand Beam Therapeutics has an analysts' consensus of $44.07 which suggests that it could grow by 108.26%. Given that Dyne Therapeutics has higher upside potential than Beam Therapeutics, analysts believe Dyne Therapeutics is more attractive than Beam Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    9 2 0
    BEAM
    Beam Therapeutics
    10 3 0
  • Is DYN or BEAM More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Beam Therapeutics has a beta of 2.076, suggesting its more volatile than the S&P 500 by 107.573%.

  • Which is a Better Dividend Stock DYN or BEAM?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Beam Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or BEAM?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Beam Therapeutics quarterly revenues of $7.5M. Dyne Therapeutics's net income of -$115.4M is lower than Beam Therapeutics's net income of -$109.3M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Beam Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 27.92x for Beam Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$115.4M
    BEAM
    Beam Therapeutics
    27.92x -- $7.5M -$109.3M
  • Which has Higher Returns DYN or NTLA?

    Intellia Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of -687.61%. Dyne Therapeutics's return on equity of -- beat Intellia Therapeutics's return on equity of -56.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$1.05 --
    NTLA
    Intellia Therapeutics
    -- -$1.10 $779.9M
  • What do Analysts Say About DYN or NTLA?

    Dyne Therapeutics has a consensus price target of $39.68, signalling upside risk potential of 359.22%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.30 which suggests that it could grow by 223.33%. Given that Dyne Therapeutics has higher upside potential than Intellia Therapeutics, analysts believe Dyne Therapeutics is more attractive than Intellia Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    9 2 0
    NTLA
    Intellia Therapeutics
    18 6 0
  • Is DYN or NTLA More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.211, suggesting its more volatile than the S&P 500 by 121.143%.

  • Which is a Better Dividend Stock DYN or NTLA?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or NTLA?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Dyne Therapeutics's net income of -$115.4M is lower than Intellia Therapeutics's net income of -$114.3M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 25.53x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$115.4M
    NTLA
    Intellia Therapeutics
    25.53x -- $16.6M -$114.3M
  • Which has Higher Returns DYN or RARE?

    Ultragenyx Pharmaceutical has a net margin of -- compared to Dyne Therapeutics's net margin of -108.46%. Dyne Therapeutics's return on equity of -- beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$1.05 --
    RARE
    Ultragenyx Pharmaceutical
    79.42% -$1.57 $151.2M
  • What do Analysts Say About DYN or RARE?

    Dyne Therapeutics has a consensus price target of $39.68, signalling upside risk potential of 359.22%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $87.84 which suggests that it could grow by 200.52%. Given that Dyne Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Dyne Therapeutics is more attractive than Ultragenyx Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    9 2 0
    RARE
    Ultragenyx Pharmaceutical
    14 1 0
  • Is DYN or RARE More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.261, suggesting its less volatile than the S&P 500 by 73.884%.

  • Which is a Better Dividend Stock DYN or RARE?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or RARE?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Dyne Therapeutics's net income of -$115.4M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 4.67x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$115.4M
    RARE
    Ultragenyx Pharmaceutical
    4.67x -- $139.3M -$151.1M
  • Which has Higher Returns DYN or RNA?

    Avidity Biosciences has a net margin of -- compared to Dyne Therapeutics's net margin of -7360.01%. Dyne Therapeutics's return on equity of -- beat Avidity Biosciences's return on equity of -29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$1.05 --
    RNA
    Avidity Biosciences
    -- -$0.90 $1.3B
  • What do Analysts Say About DYN or RNA?

    Dyne Therapeutics has a consensus price target of $39.68, signalling upside risk potential of 359.22%. On the other hand Avidity Biosciences has an analysts' consensus of $66.56 which suggests that it could grow by 111.62%. Given that Dyne Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Dyne Therapeutics is more attractive than Avidity Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    9 2 0
    RNA
    Avidity Biosciences
    13 0 0
  • Is DYN or RNA More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.908, suggesting its less volatile than the S&P 500 by 9.163%.

  • Which is a Better Dividend Stock DYN or RNA?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or RNA?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Avidity Biosciences quarterly revenues of $1.6M. Dyne Therapeutics's net income of -$115.4M is higher than Avidity Biosciences's net income of -$115.8M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 429.95x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$115.4M
    RNA
    Avidity Biosciences
    429.95x -- $1.6M -$115.8M
  • Which has Higher Returns DYN or SRPT?

    Sarepta Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of -60.08%. Dyne Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$1.05 --
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
  • What do Analysts Say About DYN or SRPT?

    Dyne Therapeutics has a consensus price target of $39.68, signalling upside risk potential of 359.22%. On the other hand Sarepta Therapeutics has an analysts' consensus of $47.96 which suggests that it could grow by 163.95%. Given that Dyne Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Dyne Therapeutics is more attractive than Sarepta Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    9 2 0
    SRPT
    Sarepta Therapeutics
    10 12 1
  • Is DYN or SRPT More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

  • Which is a Better Dividend Stock DYN or SRPT?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or SRPT?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Dyne Therapeutics's net income of -$115.4M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 0.90x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$115.4M
    SRPT
    Sarepta Therapeutics
    0.90x 20.50x $744.9M -$447.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 14

MiNK Therapeutics [INKT] is down 28.32% over the past day.

Buy
51
NEGG alert for Jul 14

Newegg Commerce [NEGG] is down 21.87% over the past day.

Buy
68
ATRO alert for Jul 14

Astronics [ATRO] is down 2.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock